Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden.
B2M mutation
TP53 mutation
XPO1 mutation
Genomic profiling
Hodgkin lymphoma
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
30
01
2018
accepted:
19
06
2018
pubmed:
16
8
2018
medline:
21
3
2020
entrez:
16
8
2018
Statut:
ppublish
Résumé
The genomic landscape of Hodgkin lymphoma (HL) has been difficult to characterize due to the paucity of neoplastic cells and an abundant microenvironment. Such characterization is needed in order to improve treatment strategies. We performed comprehensive genomic profiling (CGP) using targeted next-generation sequencing on archival formalin-fixed paraffin embedded tumor samples from 63 patients to analyze the landscape of HL. CGP was successful for 49/63 archival specimens (78%), and revealed aberrations impacting genes including The study demonstrates that comprehensive genomic profiling of archival Hodgkin lymphoma tumor samples is feasible and leads to the identification of genes that are recurrently mutated and that Hodgkin lymphoma has increased mutation burden in the majority of samples analyzed. Furthermore, tracking of This study provides the first evidence that comprehensive genomic profiling can be performed to map the genomic landscape of Hodgkin lymphoma and that a subpopulation of patients has mutations in
Sections du résumé
BACKGROUND
The genomic landscape of Hodgkin lymphoma (HL) has been difficult to characterize due to the paucity of neoplastic cells and an abundant microenvironment. Such characterization is needed in order to improve treatment strategies.
MATERIALS AND METHODS
We performed comprehensive genomic profiling (CGP) using targeted next-generation sequencing on archival formalin-fixed paraffin embedded tumor samples from 63 patients to analyze the landscape of HL.
RESULTS
CGP was successful for 49/63 archival specimens (78%), and revealed aberrations impacting genes including
CONCLUSION
The study demonstrates that comprehensive genomic profiling of archival Hodgkin lymphoma tumor samples is feasible and leads to the identification of genes that are recurrently mutated and that Hodgkin lymphoma has increased mutation burden in the majority of samples analyzed. Furthermore, tracking of
IMPLICATIONS FOR PRACTICE
This study provides the first evidence that comprehensive genomic profiling can be performed to map the genomic landscape of Hodgkin lymphoma and that a subpopulation of patients has mutations in
Identifiants
pubmed: 30108156
pii: theoncologist.2018-0058
doi: 10.1634/theoncologist.2018-0058
pmc: PMC6369943
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
219-228Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000371
Pays : United States
Informations de copyright
© AlphaMed Press 2018.
Déclaration de conflit d'intérêts
Disclosures of potential conflicts of interest may be found at the end of this article.
Références
Nat Biotechnol. 2013 Nov;31(11):1023-31
pubmed: 24142049
Nucleic Acids Res. 2015 Jan;43(Database issue):D805-11
pubmed: 25355519
Cancer Res. 2006 Nov 1;66(21):10332-8
pubmed: 17079453
J Clin Oncol. 2008 Jan 20;26(3):455-62
pubmed: 18086796
J Clin Oncol. 2012 Mar 10;30(8):777-82
pubmed: 22271473
J Pathol. 2011 Aug;224(4):564-74
pubmed: 21706479
Blood. 2000 Aug 15;96(4):1280-6
pubmed: 10942369
Blood. 2009 Nov 12;114(20):4503-6
pubmed: 19734449
Genes Dev. 2003 Aug 1;17(15):1829-34
pubmed: 12869586
J Clin Oncol. 2003 Dec 15;21(24):4505-9
pubmed: 14673037
Blood. 2010 Oct 28;116(17):3268-77
pubmed: 20628145
Oncogene. 2006 Apr 27;25(18):2679-84
pubmed: 16532038
BMC Cancer. 2012 Oct 05;12:457
pubmed: 23039325
Br J Haematol. 1998 Mar;100(4):655-63
pubmed: 9531330
Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2817-21
pubmed: 8464894
J Exp Med. 2009 May 11;206(5):981-9
pubmed: 19380639
Blood. 2016 Jun 16;127(24):3004-14
pubmed: 26966091
Biochem Pharmacol. 2012 Apr 15;83(8):1021-32
pubmed: 22209898
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84
pubmed: 18971340
Blood. 2015 Feb 12;125(7):1061-72
pubmed: 25488972
Int J Cancer. 2001 Oct 1;94(1):60-6
pubmed: 11668479
N Engl J Med. 2004 May 20;350(21):2129-39
pubmed: 15118073
J Clin Oncol. 2016 Aug 10;34(23):2690-7
pubmed: 27069084
Am J Hematol. 2016 Sep;91(9):923-30
pubmed: 27312795
Blood. 1993 Jun 1;81(11):3097-115
pubmed: 8499644
Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3879-84
pubmed: 22343534
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
Haematologica. 2016 Sep;101(9):1094-101
pubmed: 27479820
Lancet. 2012 Sep 1;380(9844):836-47
pubmed: 22835602